Kadevix Completes Nearly RMB 200 Million Series B Financing Led by Cold Fir Creek Capital to Advance Innovative Gynecologic Oncology Diagnostics and Therapeutics

Gynecological tumors are characterized by a prolonged disease course, high incidence, and strong concealment. Limited by existing diagnostic and therapeutic methods, a significant number of patients experience missed or delayed diagnoses. In recent years, the incidence of gynecological tumors such as cervical cancer, endometrial cancer, and ovarian cancer has risen significantly, with a trend toward affecting younger populations. There is an urgent clinical need for non-invasive, precise screening, diagnostic, and staging technologies, as well as effective treatment modalities.

Kaidewei was founded by Professor Ma Ding from Tongji Hospital of Huazhong University of Science and Technology, a renowned scientist and academician of the Chinese Academy of Engineering. The company has established an in-depth layout covering the entire process of screening, diagnosis, prevention, and treatment of gynecological tumors. Two of its original, first-in-class in vitro diagnostic kits have been approved for entry into the National Medical Products Administration’s Green Channel for Innovative Medical Device Review for two consecutive years. These products are expected to facilitate rapid screening and precise diagnosis and treatment of gynecological tumors such as endometrial cancer and cervical cancer, as well as their precancerous lesions, significantly improving patient accessibility while reducing unnecessary invasive procedures and medical costs. Leveraging decades of research accumulation by Academician Ma Ding’s team, the company is actively developing international frontier innovative therapies, including oncolytic viruses and therapeutic HPV vaccines. Currently, its independently developed novel recombinant oncolytic adenovirus product has been approved to enter Phase I clinical trials, holding promise for addressing the widespread efficacy issues of existing oncolytic virus products and breaking through treatment bottlenecks for patients with solid tumors such as ovarian cancer.

Martin, Founder of Kaidewei and Academician of the Chinese Academy of Engineeringstated, “The successful completion of this funding round represents strong recognition from the capital markets for our team, and even more so, steadfast support for our dedication to original innovative diagnostic and therapeutic technologies and products in gynecologic oncology, as well as our deep commitment to the field of women’s health. In the area of gynecologic oncology, we have always adhered to a patient-centric approach, driven by technological innovation, and are committed to developing more precise and effective diagnostic and treatment solutions and products. This round of financing will significantly accelerate our R&D efforts, expedite the market launch of our products, and benefit more female patients.”

“At the same time, we deeply recognize that the mutual empowerment between startups and capital markets is a significant force driving industry development. We look forward to joining hands with more like-minded partners to jointly promote the advancement of women’s health and contribute to achieving the grand goal of ‘Healthy China.’”

Huang Xiaobin, Founder of FIRHealth Capital, the Lead InvestorHe stated, “Academician Martin was the first Chief Scientist of the National 973 Program in Obstetrics and Gynecology. With decades of in-depth research across the entire spectrum of obstetric and gynecological diagnosis and treatment, he has remained at the forefront of both clinical practice and scientific research, pioneering numerous international novel gynecological technologies. He is leading Kaidewei in advancing multiple globally first-in-class IVD reagents and innovative drugs. We are honored to collaborate with Academician Martin and look forward to accelerating the development and clinical translation of our technologies, thereby ensuring that patients with gynecologic tumors receive more timely, effective, and accessible diagnosis and treatment.”

Founded in 2018, Wuhan Kaidewei Biotechnology Co., Ltd. is built around the team led by Academician Ma Ding of the Chinese Academy of Engineering and Director of the Department of Obstetrics and Gynecology at Tongji Hospital, affiliated with Tongji Medical College of Huazhong University of Science and Technology. The company specializes in diagnostic reagents, innovative biological drugs, and technology development and services, covering the entire spectrum of disease management—particularly for gynecological tumors—including early prevention, early screening, early diagnosis, intraoperative auxiliary diagnosis, and treatment. Upholding its vision to “build a new ecosystem for reproductive health in China and become a leader in gynecological diagnosis and treatment,” the company aligns with national strategic priorities and serves women’s health, striving to provide patients with effective and accessible innovative solutions throughout the entire disease journey.

FIRHealth Capital, established in 2021, is an emerging investment fund specializing in the biopharmaceutical and broader healthcare sectors. The firm focuses on innovative investments and value discovery within the global biopharmaceutical industry. Its team comprises high-caliber professionals from the industrial, scientific research, and venture capital communities, bringing extensive experience in both the pharmaceutical industry and investment. Adhering to its core philosophy of “seeking truth and being pragmatic, and dedicating meticulous effort and wisdom,” FIRHealth Capital maintains investment principles of “foresight and independence.” It is committed to creating sustained value for investors, shareholders, and society at large through rigorous project evaluation and scientific investment decision-making. As a dedicated practitioner in the healthcare sector, FIRHealth Capital not only pursues the success and returns of its investment projects but also strives to advance medical technology and improve human health. By partnering with outstanding scientists and entrepreneurs, the firm remains true to its original aspiration, jointly writing a new chapter in the life sciences.